SPORE Core C: Biostatistics Core. The research proposed by The University of Texas SPORE in Lung Cancer encompasses a broad range of activities, including studies in cell lines, animal models, and clinical trials. These studies will generate many different types of data, including not only conventional clinical, epidemiological, biochemical, and immunohistochemical measurements, but also dose response curves, gene expression microarrays, reverse phase protein lysate arrays (RPPA), cytokine assays, and assessments of the frequency of single nucleotide polymorphisms (SNPs). The Biostatistics Core provides comprehensive biostatistics expertise to ensure the statistical integrity and to optimize data analysis of the studies by the SPORE, which are conducted at the Southwestern Medical Center (UTSW) and the M.D. Anderson Cancer Center (MDACC). The Core assists investigators with the proper planning of experiments, cooperates with Core D (Bioinformatics) to manage experimental data generated by Lung SPORE projects, and conducts statistical analyses for Lung SPORE investigators. The Core has the flexibility to match personnel to the evolving needs of existing and developmental SPORE projects. Members of the Core participate in monthly SPORE video conferences linking researchers at UTSW in Dallas, TX and M.D. Anderson Cancer Center in Houston, TX, and at times investigators at other institutions (e.g. University of Texas, Austin), ensuring that proper consideration is taken of biostatistics and data management issues during all phases of SPORE experiments. To carry out its responsibilities, the Core has the following Specific Aims:
Aim 1 : To provide valid statistical designs of laboratory research, clinical trials and translational experiments arising from the ongoing research of the SPORE.
Aim 2 : To oversee and conduct the innovative statistical modeling, simulations, and data analyses needed by the Projects, Developmental and Career Projects, and the other Cores to achieve their specific aims.
Aim 3 : To ensure that the results of all Projects are based on well-designed experiments, appropriately interpreted, and to assist in the preparation of manuscripts describing these results.
Aim 4 : To work closely with Core D (Bioinformatics) in the configuration of the integrated database application programming interface (API) to facilitate automation of statistical analysis procedures and development of computational tools, and make them available to all SPORE participants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-15
Application #
8375378
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
15
Fiscal Year
2012
Total Cost
$238,548
Indirect Cost
$40,827
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Huang, Fang; Ni, Min; Chalishazar, Milind D et al. (2018) Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metab 28:369-382.e5
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Pozo, Karine; Minna, John D; Johnson, Jane E (2018) Identifying a missing lineage driver in a subset of lung neuroendocrine tumors. Genes Dev 32:865-867
Fan, C-W; Yarravarapu, N; Shi, H et al. (2018) A synthetic combinatorial approach to disabling deviant Hedgehog signaling. Sci Rep 8:1133
Cascone, Tina; McKenzie, Jodi A; Mbofung, Rina M et al. (2018) Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27:977-987.e4
Cascone, Tina; Gold, Kathryn A; Swisher, Stephen G et al. (2018) Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105:418-424
Ng, Patrick Kwok-Shing; Li, Jun; Jeong, Kang Jin et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33:450-462.e10

Showing the most recent 10 out of 1059 publications